Clene Inc. — Director's Dealing 2021

Jan 8, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Clene Inc. (CLNN)
CIK: 0001822791
Period of Report: 2020-12-30

Reporting Person: WILCOX REED N (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	19449	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Incentive Stock Option (right to buy)	$0.144		Common Stock (527911)		Direct

Footnotes

F1: Awarded the right to 4,140,000 shares of Clene Nanomedicine common stock under the Clene Nanomedicine, Inc. 2014 Stock Plan on July 3l, 2014. The reporting party exercised his right to purchase 140,000 shares of Clene Nanomedicine common stock on November 24, 2020. Following Clene Nanomedicine, Inc.'s merger, the unexercised options converted into a right to buy common stock of Clene Inc. The unexercised options now represent the right to buy 527,9 l l shares of Clene Inc. common stock. The unexercised options options are are all currently exercisable and expire 10 years from the date of the grant.